Physicians

Chief, Vitreoretinal Diseases and Surgery Service

Department / Division
Ophthalmology / Retinal Ophthalmology

Address
DUMC 3802
Durham, NC 27710

Appointment Telephone
919-681-3937

Office Telephone
919-684-6611

Fax Telephone
919-681-6474

Training

• MD, University of California–San Francisco School of Medicine, 1987

Residency

• Vitreoretinal Disease, Medical College of Wisconsin, 1987-1989

Clinical Interests
Vitreoretinal diseases and retinal cell biology, macular holes, retinal detachment, subretinal neovascularization, proliferative diabetic retinopathy, posterior segment surgical procedures for diagnosis or therapy of uveitis

Research Interests
I have an active basic and clinical research program. I have been principal investigator on several funded clinical studies including investigations of an oral ganciclovir prodrug to treat CMV retinitis and a study to determine the safety of a cyclosporine sustained drug delivery implant in the treatment of uveitis. I am principal investigator of an ongoing multicenter trial of a fluocinolone sustained drug delivery implant to treat patients with severe uveitis and a trial of this same implant to treat diabetic macular edema. Recently, I have investigated the use of ultrasonography and optical coherence tomography to diagnose macular edema in a variety of ocular diseases. I have maintained an ongoing basic research program to test the hypothesis that cytokines are important in the development of proliferative vitreoretinopathy, an important intraocular wound healing disorder. Education: I am actively involved in resident and fellow education. I give lectures to residents and fellows on a variety of topics related to uveitis and vitreoretinal diseases and train fellows to perform vitreoretinal surgery. I train post-doctoral students and medical students to conduct clinically relevant research. I serve as a mentor for the Duke third year medical school research program. I have served on a yearly basis as course faculty at many national and international meetings.

Industry Relationships and Collaborations (What's this?)

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Abbott Laboratories
• Bayer Schering Pharma AG
• Neurotech
• Pfizer Inc.

Representative Publications
Jaffe, GJ; Brownlow, R; Hines, J. Modified external needle drainage procedure for rhegmatogenous retinal detachment. Retina: the Journal of Retinal and Vitreous Diseases. 2003;23:80-85. (2003) Abstract

Lai, JC; Stinnett, SS; Jaffe, GJ. B-scan ultrasonography for the detection of macular thickening. American Journal of Ophthalmology. 2003;136:55-61. (2003) Abstract

Stamer, WD; Bok, D; Hu, J; Jaffe, GJ; McKay, BS. Aquaporin-1 channels in human retinal pigment epithelium: role in transepithelial water movement. Investigative Ophthalmology and Visual Science. 2003;44:2803-2808. (2003) Abstract

Yang, P; McKay, BS; Allen, JB; Roberts, WL; Jaffe, GJ. Effect of mutant IkappaB on cytokine-induced activation of NF-kappaB in cultured human RPE cells. Investigative Ophthalmology and Visual Science. 2003;44:1339-1347. (2003) Abstract

Meyer, CH; Hotta, K; Peterson, WM; Toth, CA; Jaffe, GJ. Effect of INS37217, a P2Y(2) receptor agonist, on experimental retinal detachment and electroretinogram in adult rabbits. Investigative Ophthalmology and Visual Science. 2002;43:3567-3574. (2002) Abstract

Mruthyunjaya, P; Jumper, JM; McCallum, R; Patel, DJ; Cox, TA; Jaffe, GJ. Diagnostic yield of vitrectomy in eyes with suspected posterior segment infection or malignancy. Ophthalmology. 2002;109:1123-1129. (2002) Abstract

Jaffe, GJ; Ben-Nun, J; Guo, H; Dunn, JP; Ashton, P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024-2033. (2000) Abstract

Jaffe, GJ; Yang, CH; Guo, H; Denny, JP; Lima, C; Ashton, P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Investigative Ophthalmology and Visual Science. 2000;41:3569-3575. (2000) Abstract

Jaffe, GJ; Yang, CS; Wang, XC; Cousins, SW; Gallemore, RP; Ashton, P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998;105:46-56. (1998) Abstract

Yang, CS; Khawly, JA; Hainsworth, DP; Chen, SN; Ashton, P; Guo, H; Jaffe, GJ. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Archives of Ophthalmology. 1998;116:69-77. (1998) Abstract

Liu, NP; Roberts, WL; Hale, LP; Levesque, MC; Patel, DD; Lu, CL; Jaffe, GJ. Expression of CD44 and variant isoforms in cultured human retinal pigment epithelial cells. Investigative Ophthalmology and Visual Science. 1997;38:2027-2037. (1997) Abstract

Merrill, PT; Kim, J; Cox, TA; Betor, CC; McCallum, RM; Jaffe, GJ. Uveitis in the southeastern United States. Current Eye Research. 1997;16:865-874. (1997) Abstract

Jaffe, GJ; Abrams, GW; Williams, GA; Han, DP. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology. 1990;97:184-189. (1990) Abstract